ABCL vs BIIB · rev $12.4M vs P/E 21, rev $9.89B
Abcellera Biologics Inc (ABCL) versus Biogen Inc (BIIB) — a side-by-side from cached financials, not a winner call.
Abcellera Biologics Inc (ABCL) is a biotechnology company listed on US.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Latest reported ABCL revenue for 2026-06-30 was $12.4M. Net income was -$98.6M. Revenue was up 48.7% from 2026-03-31 to 2026-06-30. ABCL currently screens at market cap $1.12B.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
ABCL currently screens at market cap $1.12B. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Not investment advice. Open the ABCL and BIIB stock pages for the full models.
Not investment advice.